



## Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice

Andersson, Anne Marie Carola; Holst, Peter Johannes

*Published in:*  
Journal of Translational Medicine

*DOI:*  
[10.1186/s12967-016-1102-7](https://doi.org/10.1186/s12967-016-1102-7)

*Publication date:*  
2016

*Document version*  
Publisher's PDF, also known as Version of record

*Document license:*  
[CC BY](#)

*Citation for published version (APA):*  
Andersson, A. M. C., & Holst, P. J. (2016). Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice. *Journal of Translational Medicine*, 14, [343]. <https://doi.org/10.1186/s12967-016-1102-7>

RESEARCH

Open Access



# Increased T cell breadth and antibody response elicited in prime-boost regimen by viral vector encoded homologous SIV Gag/Env in outbred CD1 mice

Anne-Marie Carola Andersson\* and Peter Johannes Holst\*

## Abstract

**Background:** A major obstacle for the development of HIV vaccines is the virus' worldwide sequence diversity. Nevertheless, the presence of T cell epitopes within conserved regions of the virus' structural Gag protein and conserved structures in the envelope (env) sequence raises the possibility that cross-reactive responses may be induced by vaccination. In this study, the aim was to investigate the importance of antigenic match on immunodominance and breadth of obtainable T cell responses.

**Methods:** Outbred CD1 mice were immunized with either heterologous (SIVmac239 and HIV-1 clade B consensus) or homologous (SIVmac239) gag sequences using adenovirus (Ad5) and MVA vectors. Env (SIVmac239) was co-encoded in the vectors to study the induction of antibodies, which is a primary target of current HIV vaccine designs. All three vaccines were designed as virus-encoded virus-like particle vaccines. Antibody responses were analysed by ELISA, avidity ELISA, and neutralization assay. T cell responses were determined by intracellular cytokine staining of splenocytes.

**Results:** The homologous Env/Gag prime-boost regimen induced higher Env binding antibodies, and induced stronger and broader Gag specific CD8+ T cell responses than the homologous Env/heterologous Gag prime-boost regimen. Homologous Env/heterologous Gag immunization resulted in selective boosting of Env specific CD8+ T cell responses and consequently a paradoxical decreased recognition of variant sequences including conserved elements of p24 Gag.

**Conclusions:** These results contrast with related studies using Env or Gag as the sole antigen and suggest that prime-boost immunizations based on homologous SIVmac239 Gag inserts is an efficient component of genetic VLP vaccines—both for induction of potent antibody responses and cross-reactive CD8+ T cell responses.

**Keywords:** Adenoviral vectors, Human immunodeficiency virus, Vaccine, Virus-like particles

## Background

The ideal human immunodeficiency virus (HIV) vaccine should likely activate both the humoral and the cellular arm of the immune system; enabling antibodies to neutralize incoming virus particles while CD8+ T cells

would kill already infected cells and limit the spread of the virus.

The substantial role of CD8+ T cells in the control of HIV type 1 (HIV-1) infection is supported by the correlate of protection with specific HLA class I allotypes [1–4], a temporary decline in peak viremia coinciding with appearance of CD8+ T cell responses during acute infection [5, 6], and occurrence of escape mutants in response to specific CD8+ T cells [7, 8]. In humans, protective CD8+ T cell responses have been found to correlate with

\*Correspondence: annema@sund.ku.dk; pholst@sund.ku.dk  
Department of Immunology and Microbiology, Center for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark

the targeting of Gag [9, 10] and possibly of Nef [11], while inversely correlating with responses against envelope (Env) [10]. These correlations have been substantiated by additional population studies that have generated in-depth data by carefully screening responses to the HIV-1 proteome and investigating protective responses towards individual epitopes [12–17]. Together, these studies indicate that it is theoretically possible to successfully target HIV-1 by inducing T cells targeting specifically effective epitopes. However, such protective T cell specificities have only been raised infrequently after immunization with full length HIV-1 antigens [18] and previous vaccination attempts that aimed to induce CD8+ T cells have failed to control HIV-1 replication overall [19]. Despite their overall clinical failure, these studies did provide evidence of improved virus control after polyspecific targeting of defined regions of Gag, Vif, Nef, and Pol [18, 20]. A shift to more focused constructs aimed to direct CD8+ T cells specifically to carefully selected regions has therefore been a logical step forward. Conserved regions vaccines [14, 21] and conserved elements (CE) vaccines [22] each represents approaches aiming to overcome the challenge of HIV-1 diversity and raise responses to rarely targeted, yet protective specificities [23].

While T cell based vaccines have yet to show efficacy in clinical trials, the RV144 trial demonstrated the possibility of reducing infection risk by raising Env specific antibodies with a virus-like particle (VLP) encoded virus vectored prime and a protein boost vaccine [24]. A recent interest in the coordinated responses against Gag and Env has emerged. Studies by Schell et al. suggested that Gag benefits a response based on protective antibodies in a vaccine secreting VLPs [25, 26]. Additionally, the immune response against Gag has been shown to support antibody responses against Env displayed on VLPs by providing an additional source of intrastructural T cell help [27, 28].

Due to the additive and potentially synergistic value of using Gag and Env for effective antibody and T cell mediated protection, we sought to study the induction of potentially protective Gag and Env responses in VLP based virus vectored immunization regimens. To investigate the possibility of inducing T cell responses against conserved or cross-reactive epitopes in the Gag polypeptide, while preserving antibody responses towards Env trimers in such a virus vectored VLP vaccine construct, we used a prime-boost regimen with heterologous Gag together with homologous Env and compared it to a homologous Gag/Env regimen. We did this by utilizing a combination of adenoviral vectors co-encoding SIVmac239 *env* and either HIV-1 or SIVmac239 *gag* sequences as primers for modified vaccinia Ankara

(MVA) vectors encoding SIVmac239 *env* and SIVmac239 *gag*. We included a non HIV sequence as previous studies have found no benefit of prime-boost regimens using Gag from different HIV clades while improved breadth was found using different HIV Env clade sequences [29, 30]. Using SIV and HIV Env provides a diversity resembling the successful heterologous Env sequences and results in a vaccine design immediately testable in a non-human primate model. Here we show that outbred CD1 mice immunized with homologous Gag/Env had an increased breadth and functionality of T cell responses against heterologous *gag* sequences as well as a surprising increased magnitude of Env specific antibody responses. Mice immunized with homologous Gag selectively expanded Gag specific T cells following the booster immunization whereas mice immunized with heterologous Gag selectively expanded Env specific T cells following the boost. These data highlights the importance in the selection of *gag* sequences in VLP encoding virus vectored immunization regimens.

## Methods

### Mice

Female CD1 mice at the age of 6–8 weeks were obtained from Scanbur (Denmark). The mice were allowed to acclimatize for one week prior to the initiation of an experiment. All experiments were performed according to national guidelines and experimental protocols approved by the national animal experiments inspectorate (Dyreforsøgstilsynet).

### Adenoviral vaccine production

HIV-1 clade B consensus (HIV-1 CON B) or SIVmac239 *gag* was encoded after a CMV promoter, followed by a self-cleavable P2A peptide and then by SIVmac239 *env* and SV40 polyA. The expression cassette was cloned into a human adenovirus type 5 backbone and produced, purified and titered as described [31]. A modified vaccinia Ankara (MVA) vaccine encoding SIVmac239 *gag*, *pol*, *env* (truncated at aa 733) (MVAgpe) [32] was kindly provided by Dr. Patricia Earl (Laboratory of Viral Diseases, NIH). The vaccine was amplified and titered in primary chicken embryoblasts according to the protocols in Kramer et al. [33].

### Purification of vaccine encoded VLPs for further characterization

Vero cells were infected with 50 plaque forming units (PFU)/cell of either Ad5 vaccine, supernatants harvested 48 h post infection, and VLPs concentrated as previously described [31]. Pellets were resuspended in PBS at 280 X of the original concentration.

### Western blot analysis

VLPs purified from Ad5 infected vero cells were prepared as previously described [31] and characterized by western blot. Env was detected with the SIVmac251 gp120 specific monoclonal antibody (mAb) KK46 [34] [NIH AIDS Research and Reference Reagent Program (NARRRP)] followed by HRP coupled goat anti-mouse immunoglobulin antibody (Dako). The same blot was analysed for the presence of Gag using HIV-1 anti-p24 mAb 183-H12-5C [35] (NARRRP), and goat anti-mouse immunoglobulin antibody (Dako). SIVmac239 gp130 [36] and SIVmac251 BK28 pr55 Gag were loaded as positive controls (NARRRP). The blots were developed using ChemiLucent Detection System kit (Pierce). Analysis was performed using Image Studio Lite software (LI-COR Biosciences).

### Cell surface expression analysis

Env expression was analysed on the surface of vero cells 2 days after infection with 50 PFU/cell of either Ad5 vaccine. Cells were stained with the ITS52, ITS03, and ITS40 mAbs [37] (kindly provided by Dr. Mario Roederer, VRC, NIAID, NIH). Binding of the mAbs was detected using anti-human IgG Fc-APC antibody (BioLegend), and the cells were acquired using an LSRII instrument (BD Biosciences) and analysed with FlowJo software (Tree Star, Ashland, OR).

### Immunizations

Groups of mice (5 or 10 per group) were immunized intramuscularly (i.m.) with  $2 \times 10^8$  IFU with either Ad5 vaccine. Where indicated, mice were boosted i.m. 59 days after priming with  $1 \times 10^7$  IFU of MVA<sub>gpe</sub>. Vaccines were applied in a total volume of 50  $\mu$ l PBS in the quadriceps muscle, changing legs at each immunization time-point.

### Antibody response measurements

Antibody responses against SIVmac239 Env were determined in a concanavalin A (ConA) (Sigma-Aldrich) enzyme linked immunosorbent assay (ELISA) as adapted from [38]. SIVmac239 Env was produced in 293FT cells by co-transfection of a shuttle plasmid encoding SIVmac239 Env and the plasmid pSG3<sup>Δenv</sup> [39] (NARRRP). ELISA was performed as described elsewhere [31]. Avidity measurements were performed simultaneously with antibody response measurements as adapted from [38], using 0.1 M sodium citrate buffer (pH 3.0). The avidity index was calculated by dividing the titer obtained with sodium citrate treatment by the titer obtained without sodium citrate treatment, and multiplied by 100.

### SIV Env pseudovirus production and titration

The Env constructs for SIVmac239 and SIVsmE660.11 pseudovirus production were obtained from Dennis

Burton (The Scripps Research Institute) and David C. Montefiori (Duke University), respectively. Production and determining TCID has been described elsewhere [40].

### Neutralization assay

Neutralization of pseudoviruses was measured in TZM-bl cells following the protocols in Montefiori [40]. To account for unspecific binding to either pseudovirus, pooled pre-immunization serum samples were analysed at a dilution of 1:20. SIVmac251 antiserum [41] (NARRRP) was included as a control. Neutralization against SIVmac239 was assayed in pools of 4–5 mice per group. The SIVmac239 pseudovirus did not achieve the RLU of 10 times the background (5.2 times the RLU of the background), but was included in the analysis since it was clear that there was no neutralization in neither sample that was tested.

### Intracellular cytokine staining

Intracellular staining was performed on splenocytes using a standard protocol [42] using 0.67  $\mu$ g/ml HIV-1 CON B Gag pool, SIVmac239 Gag pool, SIVagm vervet Gag pool, SIVmac239 Env pool, CE pools for the three different Gags respectively) (all from NARRRP) at 37 °C and 5% CO<sub>2</sub>. Based on definitions by [22], CE pools were prepared from peptides spanning the CE from whole Gag peptide sets. The following antibodies were used for detection (Biolegend): CD8\_PerCP.Cy5.5, CD4\_FITC, B220\_Pacific Blue, CD44\_APC.Cy7, IFN- $\gamma$ \_APC, TNF- $\alpha$ \_Pe.Cy7. The cells were acquired using an LSRII instrument (BD Biosciences) and analysed with FlowJo software (Tree Star, Ashland, OR). One mouse was excluded from the T cell analysis due to the collection of too few events.

### Statistical analysis

Nonparametric Mann–Whitney tests were performed for analysis of differences between the groups. Spearman rank testing followed by Holms correction for multiple comparisons was used to assess correlations. The ID50 values in the neutralization assay were calculated in Graph Pad Prism using an asymmetric curve fitting (5 parameters). Statistical analyses were performed using either the R statistical software or Graph Pad Prism. p values <0.05 were considered significant.

## Results

### Vaccine design and characterization


To enable shift of the *gag* sequence in otherwise identical viral vectored prime-boost regimens, we encoded SIVmac239 *env* with either a SIVmac239 *gag* sequence (AdSgSe), or HIV-1 CON B *gag* sequence (AdHgSe) in

individual Ad5 encoded VLP expression cassettes for use as priming vaccines (Fig. 1a). The adenovirus vectors were used as priming immunogens for MVA vectors encoding SIVmac239 *gag*, *pol* and *env* (MVA<sub>gpe</sub>) likewise designed to secrete VLPs [32]. T cell immune responses were analysed to vaccine incorporated *gag* sequences and a more distantly related *gag* sequence (SIV<sub>gmv</sub> vervet). We chose the SIVmac239 *gag* sequence and the HIV-1 CON B *gag* sequence to study heterologous Gag immunization in virus-vectorized VLPs in a vaccine design suitable for nonhuman primate testing. SIV<sub>gmv</sub> vervet was chosen to measure cross-reactive responses as it had the same sequence similarity to either HIV-1 CON B *gag* or SIVmac239 *gag*, and similar similarity to these as the similarity between HIV-1 CON B and SIVmac239 *gag* (illustrated in Fig. 1b). The two Ad5 vaccines were characterized for VLP secretion of the respective vaccine antigens in the supernatant of vaccine infected vero cells. VLPs were collected and Gag and Env content was assessed by western blotting (Fig. 1c). We detected the expression of Gag with the HIV-1 p24 mAb 183-H12-5C, previously shown to cross-react with SIVmac239 Gag [43]. Bands for both pr55 and pr55 cleavage products were observed for both constructs. For Env, both gp120 and gp160 bands were visible by probing with the gp120 specific mAb KK46. The MVA<sub>gpe</sub> vaccine had been characterized previously and this analysis was not repeated here except for verification of Env expression by immunocytochemistry (not shown and [32, 44]).

Surface staining of vero cells confirmed the expression of Env from both Ad5 vaccines. An increase in cell surface binding for the three antibodies utilized for analysis (ITS52, ITS03, ITS40) was observed for the vaccine AdHgSe compared to the AdSgSe vaccine (Fig. 1d). Both vaccines exhibited lower binding to the V3 specific mAb ITS52 as compared to the V2 specific mAbs ITS03 and ITS40, but except for the quantitative difference in cell surface binding, the two vaccines stained similarly with each antibody indicating similar presentation of the conformational epitopes recognized by these antibodies [37], (Fig. 1e).


#### Heterologous and homologous Gag prime-boost regimen

The use of the two adenovirus vectors, AdHgSe and AdSgSe, and the MVA<sub>gpe</sub> vector allowed us to prime with either HIV-1 CON B Gag or SIVmac239 Gag followed by boost with SIVmac239 Gag, while keeping the SIVmac239 Env constant in the prime-boost regimen. Blood samples for antibody analysis were taken a week prior to boosting immunization and also 10 days post boost, at the same time as the spleens were harvested for T cell analysis (Fig. 2a), as this was anticipated as the time of maximal T cell responses [45] and peak antibody responses following an MVA booster immunization [46].



**Fig. 1** Vaccine design and vaccine characterization. **a** Schematic representation of Ad5 vectors encoding either SIVmac239 *gag* or HIV-1 CON B *gag*, P2A preceded by a glycine-serine-glycine linker (not noted in the figure), and SIVmac239 *env*. The inserted antigens were flanked by huCMV and a SV40 polyadenylation signal. **b** Phylogenetic tree of Gag used in the Ad5 vaccines and for analysis. The distance values show the number of substitutions as a proportion of the length of the alignment (here excluding gaps). **Upper panel** is analysis of Gag and lower panel is analysis of p24 CE. *Mu* murine leukemia virus, used as an outlier; *H* HIV-1 CON B Gag; *M* SIVmac239 Gag; *V* SIV<sub>gmv</sub> vervet Gag. **c** Gp160 and gp120 were detected in ultra centrifuge purified VLPs from the supernatants of Ad5 infected vero cells by SDS-PAGE (reduced) followed by western blot. SIVmac251 specific mAb KK46 was used for detection of gp120. Pr55 Gag and pr55 Gag cleavage products were detected using 183-5C-H12 HIV-1 p24 specific mAb. SIVmac239 gp130 and SIVmac251 BK28 pr55 Gag served as positive controls for gp120 and pr55 respectively. **c** is control lane. **d** Surface staining of vero cells infected with Ad5 vaccines (50 PFU/cell, 25 µg/ml mAb) or uninfected with indicated mAbs. **e** Ratio of AdHgSe to AdSgSe mAb binding calculated as mean fluorescence intensity × positively gated fraction. Calculations were performed on cells infected with 50 PFU/cell of either vaccine as in **d**, using 25 or 2.5 µg/ml mAb concentration. Shown are calculated ratios from two independent assays with the mean marked by horizontal lines





### Humoral responses

Env responses against VLP derived SIVmac239 Env were analysed 52 days post 1st immunization (Ad5) and 10 days post (d. 69) the second immunization (MVA). Differences in immune responses were observed between the two Ad5 priming regimens both after the first immunization and after the MVAgpe boost (Fig. 2b). Mice primed with AdSgSe had significantly higher end point titers against pseudovirus derived Env at both time-points ( $p < 0.05$  and  $< 0.01$ , respectively). Boosting with MVAgpe increased the mean responses eightfold for the AdSgSe primed group, and fourfold for the AdHgSe primed group. Mice that had only been primed with either Ad5 vaccine showed approximately a twofold decrease in Env responses after 69 days as compared to 52 days post immunization. Still, at this time-point, 69 days post immunization; titers remained significantly higher for the group immunized with AdSgSe as compared to AdHgSe ( $p < 0.05$ ).

The immunoglobulin avidity was also determined in the two groups of mice that had received boosting immunizations with no observed differences in the immunoglobulin avidity index between the immunization regimens either before or after the boost (data only shown after boost) (Fig. 2c).

Neutralizing responses were determined against SIVsmE660.11, categorized as a neutralization sensitive tier 1 [47]. The ID50 titers were analysed for the two groups of mice that had been boosted with MVAgpe. Mice primed with AdSgSe, all had detectable ID50 titers, while the ID50 titers of 3 mice in the AdHgSe primed group were below the chosen start dilution of 1:500 for detection (Fig. 2d). The geometric mean titers were similar; hence, no significant differences were detected. Neutralization was also analysed in pools of 4–5 mice against the homologous SIVmac239, classified as a neutralization resistant tier 3, with no neutralizing responses detected (data not shown).

### T cell responses to homologous and distantly related Gag sequences

The frequency and epitope specificity of T cell responses were analysed by intracellular cytokine staining on splenocytes 10 days after the MVA boost (69 days post prime). Responses were analysed against the vaccine antigens, and against SIVagm vervet Gag (Fig. 1b), to reveal the breadth and/or the cross-specificity of the responses. The homologous boost was found to increase mean responses towards all 3 complete Gag peptide pools, whereas the heterologous boost induced HIV-1 CON B

biased responses that were not increased after the boost (Fig. 3a). Also, quite prominently, the homologous Gag immunization induced significantly higher CD8 + IFN- $\gamma$  responses against SIVagm vervet Gag. Examination of T cell responses to CE within p24 of Gag revealed that heterologous Gag immunization was not beneficial for the induction of conserved p24 responses either (Fig. 3b). Instead, homologous Gag immunization induced significantly higher CD8 + IFN- $\gamma$  responses against SIVagm vervet CE, with similar responses towards the CE in HIV-1 CON B Gag. A generally higher magnitude of responses against SIVmac239 Gag CE was also observed in the homologous vaccination group compared to the heterologous vaccination group, and prominent responders was restricted to this group (5/10), but this difference was not significant using non-parametric statistics.

Analysis of the frequency of T cell responses against SIVmac239 Env showed that heterologous Gag immunization led to significantly higher CD8 + IFN- $\gamma$  responses against SIVmac239 Env ( $p < 0.05$ ) (Fig. 4). The MVA

immunization increased the responses by 30-fold in this group as compared to homologous Gag where the responses were insignificantly expanded, and only by approximately fourfold. The CD4+ T cell responses against Env in these two groups were very similar (Fig. 4).

CD4 + T cell responses were also determined against whole protein of Gag variants and CE variants revealing generally low numbers of CD4 + IFN- $\gamma$  responses against variants of Gag and CE (Fig. 5a, b).


#### Correlations between different T cell specificities and between T cells and antibody responses

Spearman rank correlations were determined within the groups for the measured Gag specific CD8+ T cell specificities and the multiple comparisons were corrected using Holm's correction. Possible synergistic T and B cell responses were also addressed.


In homologous Gag immunization, CD8 + IFN- $\gamma$  responses against SIVagm vervet CE correlated with HIV-1 CON B CE CD8 + IFN- $\gamma$  responses ( $p < 0.05$ ) (Fig. 6a). Similarly, CD8 + IFN- $\gamma$  responses against SIVmac239 CD8 + IFN- $\gamma$  CE responses correlated with HIV-1 CON B CE CD8 + IFN- $\gamma$  responses ( $p < 0.05$ ), but not significantly with SIVagm vervet CE responses following correction for multiple comparisons.

In heterologous immunization, CD8 + IFN- $\gamma$  responses against SIVagm vervet Gag correlated with its CE response (Fig. 6b).


Notably, the heterologous vaccination regimen showed a negative correlation between CD8 + IFN- $\gamma$  T cell



**Fig. 3** Heterologous Gag immunization does not induce more cross reactive T cell responses. At day 69 mice were sacrificed and spleens were harvested for analysis of vaccine induced T cell responses against HIV-1 CON B Gag, SIVmac239 Gag, and SIVagm vervet Gag. **a** Number of IFN- $\gamma$  positive CD8+ T cells measured at day 69 against full length Gag. **b** Number of IFN- $\gamma$  positive CD8+ T cells measured at day 69 against CE of the three Gag variants. Shown are calculated total numbers of responding CD8+ T cells per spleen of individual mice. Horizontal lines depict the mean of the groups




**Fig. 4** Heterologous Gag immunization induces high numbers of Env specific CD8+ T cells. Mice were analysed for respective CD4+ and CD8+ T cell responses at day 69 upon sacrifice and harvest of spleens for analysis. Frequency of IFN- $\gamma$  positive CD8+ and CD4+ T cells against SIVmac239 Env. Shown are calculated total numbers of responding CD8+ T cell per spleen of individual mice. Horizontal lines depict the mean of the groups



responses against Env to neutralizing antibody responses against SIVsmE.660.11 ( $p < 0.05$ ), but a positive correlation trend with the avidity of anti-Env immunoglobulins ( $p = 0.05454$ ) (Fig. 6d). No correlations between CD8 + IFN- $\gamma$  responses against Env and humoral responses were observed for the homologous vaccination regimen (Fig. 6c).

### Discussion

The effect of the VLP scaffold Gag on the strength of virus encoded VLP vaccine induced T cell and antibody response has not been investigated previously, nor has the effect of using different gag sequences in heterologous prime-boost VLP encoding vaccines. In our analysis of antibody responses we found significantly higher Env immunoglobulin titers induced by the homologous Gag prime-boost regimen. In contrast, the two different immunization regimens induced similar levels of neutralizing antibodies against the neutralization sensitive tier 1 SIVsmE660.11, and also similar avidity of anti-Env antibodies. More interesting, in addition to higher Env binding titers, the analysis of T cell responses revealed a superiority of the homologous Gag regimen; also at inducing broader CD8+ T cell responses against Gag.





Interestingly, and perhaps retrospectively explainable, it appeared that while Gag showed expected CD8<sup>+</sup> T cell immunodominance over Env, homologous Env showed immunodominance over heterologous Gag in a prime-boost regimen.

Our investigation of conserved T cell responses and the selection of CE peptide pools for analysis has its foundation in studies by Kulkarni et al. [22, 23, 48], who have designed an antigen combining only conserved parts of p24 of Gag that normally correlates with increased virus control, and are found to include epitopes that cannot be mutated without virus fitness loss. Our homologous full-length Gag prime-boost regimen increased both the magnitude and breadth to full length Gag variants and CE, with the induced CE responses generally correlating with the overall responses to different virus variants. Bimodal responses were observed in particular for CE for both CD4<sup>+</sup> and CD8<sup>+</sup> T cells, reflecting the harbouring of different MHC alleles in CD1 mice. Heterologous Gag immunization did induce some CE responses, albeit not the cross-reactive responses that we had expected, reflecting the preferential Env specific T cell expansion in this group that appeared to come at the expense of negligible boosting of Gag specific responses. Compared to our results, Kaufman et al. reported an intermediate effect where heterologous full length insert in a prime-boost regimen neither increased, nor decreased the responses against conserved epitopes of Gag, but this included the weakly immunogenic Ad35 vector in the prime-boost regimen and no *env* was encoded [29]. The inclusion of Env in our prime-boost vaccinations likely makes a profound difference as the MVA immunization only boosted homologous CD8<sup>+</sup> T cell responses in our study, and it would appear that homologous responses must have blocked expansion of potentially cross-reactive T cells recognizing the heterologous boosted antigens. A mechanism for how such preferential boosting of homologous antigens can increase breadth, as compared to a heterologous boost where conserved sequence specific T cells are preferentially re-stimulated, may have been provided by Kelly et al. [49] who found dominant and highly immunogenic epitopes to be effective at selecting for cross-reactive T cell responders, and Varela-Rohena et al. [50] who observed increased cross-reactivity of T cell receptors mutated for increasing affinity.

With regards to antibodies, both of the prime-boost immunization regimens analysed here had increasing antibody titers after being boosted. The priming vaccine encoding HIV-1 CON B *gag* was inferior in priming Env responses, having significantly lower antibody titers 7 weeks after priming and also 10 weeks post priming. These results implicate the benefit of SIVmac239 Gag as a VLP scaffold for induction of a binding antibody,

although we could not observe any clear differences in the VLPs or transduced cells likely to explain this benefit. We also observed a fourfold difference in the geometric mean titers between the boosted groups; however, both the avidity of the anti-Env responses and neutralizing responses against SIVsmE660.11 were roughly similar.

An intriguing aspect of our findings is if the immunodominance interplay between Gag and Env and potentially other antigens in prime-boost regimens is also playing a role after infection in vaccinated hosts. We have observed vaccine induced changes in post-exposure epitope targeting in inbred animals challenged with lymphocytic choriomeningitis virus [51], but this study is the first to report Env immunodominance over Gag at the whole antigen level in outbred animals. In SIV models, immunodominant responses towards easily mutated epitopes have been found to delay responses towards other epitopes that are harder for the virus to mutate, thus reducing the effect of vaccination [52]. In summary, our study demonstrates that interantigenic immunodominance is a critical parameter in prime-boost regimens. Future optimization of this and related regimens should include both heterologous Env and homologous SIV Gag antigens before nonhuman primate efficacy trials.

## Conclusions

Our study demonstrates the profound impact the choice of Gag can have, when used as a VLP scaffold in prime-boost regimens, on both antibody responses and T cell responses. The broad and increased T cell responses induced by homologous Gag immunization also implicate that these widely sought after responses can be induced by full length protein in most animals, while obtaining humoral responses against Env. Future studies should include analysis of Gag and CE responses to more distant Gag sequences, to provide an even broader knowledge of the perspective of homologous virus encoded VLP vaccines.

## Abbreviations

Env: envelope; VLP: virus-like particle; HIV: human immunodeficiency virus; CE: conserved elements; MVA: modified vaccinia ankara; Ad: adenovirus; CON B: clade B consensus; mAb: monoclonal antibody; i.m.: intramuscularly; ConA: concanavalin A; AdSgSe: huAd5 encoding SIVmac239 *env* with a SIVmac239 *gag* sequence; AdHgSe: huAd5 encoding SIVmac239 *env* with a HIV-1 CON B *gag* sequence; MVAgpe: MVA vector encoding SIVmac239 *gag*, *pol* and *env*; PFU: plaque forming units; PBS: phosphate buffered saline; HRP: horseradish peroxidase.

## Authors' contributions

ACA contributed to study design, performed experiments, data analysis, contributed to interpretations of results and wrote the manuscript. PJH contributed to study design, interpretations of the results and commented on the manuscript and data presentation. Both authors read and approved the final manuscript.

## Acknowledgements

We would like to thank Birta Kjaerbaek Fritlidsdottir for her administrative and technical assistance, Bang Nguyen for technical assistance, and Anders Tolver for assisting with statistical analyses. We kindly thank Dr. Karen Kent and Miss Caroline Powell (KK46 mAb), Dr. Bruce Chesebro and Kathy Wehrly (HIV-1 p24 Monoclonal Antibody (183-H12-5C)), Drs. John C. Kappes and Xiaoyun Wu (TZM-bl cell line and pSG3<sup>Δenv</sup> plasmid), and Tranzyme Inc. (TZM-bl cell line) for contributing reagents through the NIH AIDS Research and Reference Reagent Program. We thank the NIH AIDS Research and Reference Reagent Program for providing SIVmac239 gp130, SIVmac251 antiserum, SIVmac251 BK28 pr55 Gag Recombinant Protein, and SIVmac239 Env, SIVmac239 Gag, SIVagm Vervet Gag, HIV-1 consensus B Gag Peptide Sets.

## Competing interests

The authors declare that they have no competing interests.

## Availability of data and material

All relevant data needed to interpret the study is included within this publication. Unique materials generated in the study are available for non-commercial purposes.

## Ethics approval and consent to participate

The animal studies have been approved by the national oversight committee on the experimentation on animals (ref. ID: 2011/561-120) and relies exclusively on purpose bred experimental animals.

## Funding

This work was supported by the Lundbeck foundation, the AIDS foundation, the Arvid Nilssons foundation, the foundation for the Advancement of Medical Sciences, and the Axel Muusfeldt's foundation.

Received: 12 October 2016 Accepted: 30 November 2016

Published online: 20 December 2016

## References

- Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, et al. Common genetic variation and the control of HIV-1 in humans. *PLoS Genet*. 2009;5:e1000791.
- International HIVCS, Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, Ripke S, Brumme CJ, Pulit SL, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. *Science*. 2010;330:1551–7.
- Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, Burgett N, Swartz ME, Yang A, Alter G, et al. HLA alleles associated with delayed progression to AIDS contribute strongly to the initial CD8(+) T cell response against HIV-1. *PLoS Med*. 2006;3:e403.
- Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C, Coovadia H, Walker BD, Heckerman D, Goulder PJ. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. *J Virol*. 2010;84:9879–88.
- Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol*. 1994;68:6103–10.
- Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol*. 1994;68:4650–5.
- Price DA, Goulder PJ, Klennerman P, Sewell AK, Easterbrook PJ, Troop M, Bangham CR, Phillips RE. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. *Proc Natl Acad Sci USA*. 1997;94:1890–5.
- Borrow P, Lewicki H, Wei X, Horwitz MS, Pfeffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. *Nat Med*. 1997;3:205–11.
- Masemola A, Mashishi T, Khoury G, Mohube P, Mokgotho P, Vardas E, Colvin M, Zijenah L, Katzenstein D, Musonda R, et al. Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load. *J Virol*. 2004;78:3233–43.
- Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. *Nat Med*. 2007;13:46–53.
- Adland E, Carlson JM, Paioni P, Klooverpris H, Shapiro R, Ogwu A, Riddell L, Luzzi G, Chen F, Balachandran T, et al. Nef-specific CD8+ T cell responses contribute to HIV-1 immune control. *PLoS ONE*. 2013;8:e73117.
- Mothe B, Llano A, Ibarondo J, Zamarreno J, Schiaulini M, Miranda C, Ruiz Riold M, Berger CT, Herrero MJ, Palou E, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. *PLoS ONE*. 2012;7:e29717.
- Mothe B, Llano A, Ibarondo J, Daniels M, Miranda C, Zamarreno J, Bach V, Zuniga R, Perez-Alvarez S, Berger CT, et al. Definition of the viral targets of protective HIV-1-specific T cell responses. *J Transl Med*. 2011;9:208.
- Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V, Valentin A, Alicea C, Pilkington GR, Sardesai NY, et al. A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques. *J Transl Med*. 2015;13:60.
- Sunshine J, Kim M, Carlson JM, Heckerman D, Czartoski J, Migueles SA, Maenza J, McElrath MJ, Mullins JI, Frahm N. Increased sequence coverage through combined targeting of variant and conserved epitopes correlates with control of HIV replication. *J Virol*. 2014;88:1354–65.
- Pereyra F, Heckerman D, Carlson JM, Kadie C, Soghoian DZ, Karel D, Goldenthal A, Davis OB, DeZiel CE, Lin T, et al. HIV control is mediated in part by CD8+ T-cell targeting of specific epitopes. *J Virol*. 2014;88:12937–48.
- Mudd PA, Martins MA, Ericson AJ, Tully DC, Power KA, Bean AT, Piaskowski SM, Duan L, Seese A, Gladden AD, et al. Vaccine-induced CD8+ T cells control AIDS virus replication. *Nature*. 2012;491:129–33.
- Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, Payne TL, Berrong M, Ferrari G, Chopera D, et al. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses. *PLoS Pathog*. 2015;11:e1004658.
- Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. *N Engl J Med*. 2013;369:2083–92.
- Janes H, Friedrich DP, Krambrink A, Smith RJ, Kallas EG, Horton H, Casimiro DR, Carrington M, Geraghty DE, Gilbert PB, et al. Vaccine-induced gag-specific T cells are associated with reduced viremia after HIV-1 infection. *J Infect Dis*. 2013;208:1231–9.
- Rosario M, Bridgeman A, Quakkelaar ED, Quigley MF, Hill BJ, Knudsen ML, Ammendola V, Ljungberg K, Borthwick N, Im EJ, et al. Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques. *Eur J Immunol*. 2010;40:1973–84.
- Kulkarni V, Valentin A, Rosati M, Rolland M, Mullins JI, Pavlakis GN, Felber BK. HIV-1 conserved elements p24CE DNA vaccine induces humoral immune responses with broad epitope recognition in macaques. *PLoS ONE*. 2014;9:e111085.
- Kulkarni V, Valentin A, Rosati M, Alicea C, Singh AK, Jalah R, Broderick KE, Sardesai NY, Le Gall S, Mothe B, et al. Altered response hierarchy and increased T-cell breadth upon HIV-1 conserved element DNA vaccination in macaques. *PLoS ONE*. 2014;9:e86254.
- Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med*. 2012;366:1275–86.
- Schell JB, Bahl K, Foltz-Stogniew E, Rose N, Buonocore L, Marx PA, Gambhira R, Rose JK. Antigenic requirement for Gag in a vaccine that protects against high-dose mucosal challenge with simian immunodeficiency virus. *Virology*. 2015;476:405–12.
- Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Gambhira R, Tang H, Montefiori DC, et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. *J Virol*. 2011;85:5764–72.
- Nabi G, Genannt Bonsmann MS, Tenbusch M, Gardt O, Barouch DH, Temchura V, Ueberl K. GagPol-specific CD4(+) T-cells increase the antibody response to Env by intrastructural help. *Retrovirology*. 2013;10:117.

28. Genannt Bonsmann MS, Niezold T, Hannaman D, Uberla K, Tenbusch M. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8(+) T cell responses. *Vaccine*. 2016;34:1744–51.
29. Kaufman DR, Li F, Cruz AN, Self SG, Barouch DH. Focus and breadth of cellular immune responses elicited by a heterologous insert prime-boost vaccine regimen in rhesus monkeys. *Vaccine*. 2012;30:506–9.
30. Walsh SR, Moodie Z, Fiore-Gartland AJ, Morgan C, Wilck MB, Hammer SM, Buchbinder SP, Kalams SA, Goepfert PA, Mulligan MJ, et al. Vaccination with heterologous HIV-1 envelope sequences and heterologous adenovirus vectors increases T-cell responses to conserved regions: HVTN 083. *J Infect Dis*. 2016;213:541–50.
31. Andersson AC, Ragonnaud E, Seaton KE, Sawant S, Folgori A, Colloca S, Labranche C, Montefiori DC, Tomaras GD, Holst PJ. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations. *Vaccine*. 2016;34:5344–51.
32. Van Rompay KK, Greenier JL, Cole KS, Earl P, Moss B, Steckbeck JD, Pahar B, Rourke T, Montelaro RC, Canfield DR, et al. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. *J Virol*. 2003;77:179–90.
33. Kremer M, Volz A, Kreijtz JH, Fux R, Lehmann MH, Sutter G. Easy and efficient protocols for working with recombinant vaccinia virus MVA. *Methods Mol Biol*. 2012;890:59–92.
34. Kent K, Rud E, Corcoran T, Powell C, Thiriart C, Collignon C, Stott E. Identification of two neutralizing and 8 non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. *AIDS Res Hum Retroviruses*. 1992;8:1147–51.
35. Wehrly K, Chesebro B. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. *Methods*. 1997;12:288–93.
36. Hill CM, Deng H, Unutmaz D, Kewalramani VN, Bastiani L, Gorny MK, Zolla-Pazner S, Littman DR. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor. *J Virol*. 1997;71:6296–304.
37. Mason RD, Welles HC, Adams C, Chakrabarti BK, Gorman J, Zhou T, Nguyen R, O'Dell S, Lusvarghi S, Bewley CA, et al. Targeted isolation of antibodies directed against major sites of SIV Env vulnerability. *PLoS Pathog*. 2016;12:e1005537.
38. Lai L, Vodros D, Kozlowski PA, Montefiori DC, Wilson RL, Akerstrom VL, Chennareddi L, Yu T, Kannanganat S, Ofielu L, et al. GM-CSF DNA: an adjuvant for higher avidity IgG, rectal IgA, and increased protection against the acute phase of a SHIV-89.6P challenge by a DNA/MVA immunodeficiency virus vaccine. *Virology*. 2007;369:153–67.
39. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, Kilby JM, Saag MS, Wu X, Shaw GM, Kappes JC. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. *Antimicrob Agents Chemother*. 2002;46:1896–905.
40. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. *Methods Mol Biol*. 2009;485:395–405.
41. Reimann KA, Tenner-Racz K, Racz P, Montefiori DC, Yasutomi Y, Lin W, Ransil BJ, Letvin NL. Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. *J Virol*. 1994;68:2362–70.
42. Ragonnaud E, Andersson AM, Pedersen AE, Laursen H, Holst PJ. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression. *Vaccine*. 2016;34:2147–56.
43. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, Fofana IB, Johnson WE, Westmoreland S, Evans DT. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. *PLoS Pathog*. 2009;5:e1000429.
44. Earl PL, Wyatt LS, Montefiori DC, Bilska M, Woodward R, Markham PD, Malley JD, Vogel TU, Allen TM, Watkins DJ, et al. Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. *Virology*. 2002;294:270–81.
45. Capone S, Naddeo M, D'Alise AM, Abbate A, Grazioli F, Del Gaudio A, Del Sorbo M, Esposito ML, Ammendola V, Perretta G, et al. Fusion of HCV non-structural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates. *Mol Ther*. 2014;22:1039–47.
46. Kwa S, Lai L, Gangadhara S, Siddiqui M, Pillai VB, Labranche C, Yu T, Moss B, Montefiori DC, Robinson HL, et al. CD40L-adjuvanted DNA/modified vaccinia virus Ankara simian immunodeficiency virus SIV239 vaccine enhances SIV-specific humoral and cellular immunity and improves protection against a heterologous SIVE660 mucosal challenge. *J Virol*. 2014;88:9579–89.
47. Kilgore KM, Murphy MK, Burton SL, Wetzell KS, Smith SA, Xiao P, Reddy S, Francella N, Sodora DL, Silvestri G, et al. Characterization and implementation of a diverse simian immunodeficiency virus SIVsm envelope panel in the assessment of neutralizing antibody breadth elicited in rhesus macaques by multimodal vaccines expressing the SIVmac239 envelope. *J Virol*. 2015;89:8130–51.
48. Kulkarni V, Rosati M, Valentin A, Ganneru B, Singh AK, Yan J, Rolland M, Alicea C, Beach RK, Zhang GM, et al. HIV-1 p24(gag) derived conserved element DNA vaccine increases the breadth of immune response in mice. *PLoS ONE*. 2013;8:e60245.
49. Kelly C, Swadling L, Brown A, Capone S, Folgori A, Salio M, Klenerman P, Barnes E. Cross-reactivity of hepatitis C virus specific vaccine-induced T cells at immunodominant epitopes. *Eur J Immunol*. 2015;45:309–16.
50. Varela-Rohena A, Molloy PE, Dunn SM, Li Y, Suhoski MM, Carroll RG, Milicic A, Mahon T, Sutton DH, Laugel B, et al. Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. *Nat Med*. 2008;14:1390–5.
51. Holst PJ, Jensen BA, Ragonnaud E, Thomsen AR, Christensen JP. Targeting of non-dominant antigens as a vaccine strategy to broaden T-cell responses during chronic viral infection. *PLoS ONE*. 2015;10:e0117242.
52. Ishii H, Kawada M, Tsukamoto T, Yamamoto H, Matsuoka S, Shiino T, Takeda A, Inoue M, Iida A, Hara H, et al. Impact of vaccination on cytotoxic T lymphocyte immunodominance and cooperation against simian immunodeficiency virus replication in rhesus macaques. *J Virol*. 2012;86:738–45.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

